Lilly’s Mirikizumab shows reduction of Intestinal Inflammation in Crohn’s Disease
Eli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreEli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreAbbott declared the first patient has been enrolled in the DISTINCT study (Dorsal spInal cord STImulatioN vs mediCal management for
Read moreInterim analysis of the J&J COVID-19 vaccine candidate (JNJ-78436735) in the ongoing Phase 1/2a clinical trial has shown that a
Read moreSwiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read morePhase 3 clinical trials for the COVID-19 vaccine named AZD1222, developed by AstraZeneca and Oxford University, have been paused after
Read moreEli Lilly and Company announced the start of BLAZE-2, a Phase 3 study of the monoclonal antibody LY-CoV555 vaccine candidate
Read moreSanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read moreResults from the ongoing Phase I/II COVID-19 vaccine trial, led by the University of Oxford, showed the AZD1222 vaccine developed
Read moreModerna’s COVID-19 vaccine candidate generated antibodies in all 45 patients studied in its early stage human trial, the U.S biotech
Read moreAt a time when pharma and biotech companies worldwide are racing to develop a vaccine, researchers at the University of
Read more